-
The current epidemic situation is still developing rapidly, the prevention and control situation is grim and complicated
Time of Update: 2021-11-11
National Health Commission spokesperson Mi Feng said at a press conference on the State Council’s Joint Prevention and Control Mechanism on the 30th that recently, foreign epidemics are still at a high prevalence level, and the epidemic situation in some neighboring countries is rising rapidly, and China’s foreign anti-import pressure continues to increase .
-
Health Commission: 92 newly diagnosed cases on the 31st, 59 of which are in the local area
Time of Update: 2021-11-11
As of 24:00 on October 31, according to reports from 31 provinces (autonomous regions and municipalities) and the Xinjiang Production and Construction Corps, there are 869 confirmed cases (including 33 severe cases), a total of 91,738 cured and discharged cases, and a total of 4,636 deaths.
-
Health Commission: 64 newly diagnosed cases on the 28th, including 48 local
Time of Update: 2021-11-11
As of 24:00 on October 28, according to reports from 31 provinces (autonomous regions and municipalities) and the Xinjiang Production and Construction Corps, there are currently 701 confirmed cases (including 38 severe cases), a total of 91665 cured and discharged cases, and a total of 4636 deaths.
-
[Heavyweight] Yuandong’s first oral hypoglycemic drug will be approved, targeting Hausen’s star products
Time of Update: 2021-11-11
Figure 1: Yuandong's registration progress of repaglinide and metformin tablets Source: NMPA official website Repaglinide Metformin Tablets is a compound hypoglycemic drug that combines two different mechanisms of action to improve the blood sugar control of patients with type 2 diabetes.
-
Dean of Space Center Hospital: Treating "Space Diseases" and Protecting "Flying Dreams"
Time of Update: 2021-11-11
Title: Treating "Space Diseases" and Protecting "Flying Dreams" -Interview with Du Jichen, Dean of Space Center HospitalDean Xinhua News Agency reporter Jiang Lin Among the 6th National Outstanding Professional and Technical Talents commended on the 28th, there was a special doctor .
-
Who gets the booster shot of the new coronavirus vaccine?
Time of Update: 2021-11-11
Experts respond to focal issues According to the results of expert research and demonstration and the needs of epidemic prevention and control, the State Council's joint prevention and control mechanism recently launched the new coronavirus vaccine strengthened immunization work .
-
Disease control experts: vigilant against the complex situation of influenza and the new crown co-epidemic
Time of Update: 2021-11-11
In addition, the increase in cases of other respiratory viruses, including respiratory syncytial virus, will also complicate the prevention and control of respiratory infectious diseases in future epidemic seasons .
-
Health Commission: Cut off the chain of transmission!
Time of Update: 2021-11-11
Epidemic prevention and control measures need to speed up and improve quality National Health Commission: Cut the transmission chain!
Epidemic prevention and control measures should be accelerated and improved.
National Health Commission: Cut off the chain of transmission!
-
21 provinces!
Time of Update: 2021-11-05
The summary is as follows:Fujian ProvinceFujian ProvinceOn September 28, the Fujian Provincial Medical Insurance Bureau and the Fujian Provincial Health Commission issued the "Notice on Implementing the Fifth Batch of National Organizations for Centralized Procurement and Use of Drugs", announcing that the fifth batch of nationally selected 61 selected varieties will be held in October 2021.
-
5 kinds of anti-tumor drug instructions add children's drug information
Time of Update: 2021-11-05
Recently, the official website of the State Food and Drug Administration issued an announcement stating that the domestically marketed cisplatin injections, ifosfamide for injection, azathioprine tablets, asparaginase for injection and vindesine sulfate for injection, 5 anti-tumor drugs correspond to For specifications, please refer to the announcement request to submit a supplementary application for revision of the instructions to add information on children's medications .
-
Kelun Pharmaceutical's Gadoxetate Disodium Injection Obtained Drug Registration Approval
Time of Update: 2021-11-05
After review, the drug meets the relevant requirements of drug registration, approved for registration, and issued a drug registration certificate for the detection of focal liver lesions .
Compared with other MRI contrast agents, it can improve the detection rate of focal liver lesions and the accuracy of qualitative diagnosis, especially for small lesions.
-
CSPC will win $9 billion star anticoagulant
Time of Update: 2021-11-05
In 2020, Bristol-Myers Squibb’s Eliquis global sales exceeded 9 billion U.
In 2020, Bristol-Myers Squibb's Eliquis (apixaban tablets) global sales exceeded 9.
Bristol-Myers Squibb Eliquis global sales (unit: million dollars)Source: Mynet.
-
Merck is sued by insurance company for delaying the listing of generic cholesterol drug Zetia
Time of Update: 2021-11-05
The two insurance companies accused Merck of using a "monopoly plan" to delay the listing of a generic drug for the blockbuster cholesterol drug Zetia, causing insurance companies to pay higher prices for the drug over the years .
-
Pfizer's oral JAK inhibitor Xeljanz receives two new indications in the EU
Time of Update: 2021-11-05
CompilationTom LeeA few days ago, the European Commission (EC) announced the approval of Pfizer’s JAK inhibitor oral drug Xeljanz (tofacitinib) for the treatment of young children with active polyarticular joints who are two years of age and older who have first used anti-rheumatic drugs (DMARDs) and have poor response to treatment.
-
Cholangiocarcinoma therapy Gavo-cel received FDA orphan drug designation
Time of Update: 2021-11-05
The company's TRuC-T cell candidate product Gavo-cel, which targets solid tumors, is currently being studied in phase 1/2 clinical trials to treat mesothelin-positive non-small cell lung cancer (NSCLC), ovarian cancer, and malignant pleura/peritoneum Mesothelioma and cholangiocarcinoma .
-
Hisun Pharmaceutical's Valsartan Tablets Passed the Consistency Evaluation of Generic Drugs
Time of Update: 2021-11-05
On August 23, Hisun Pharmaceutical issued an announcement stating that the company had recently received the "Drug Registration Certificate" for valsartan tablets approved and issued by the State Drug Administration .
-
Bojian Alzheimer's Disease New Drug Regeneration Waves!
Time of Update: 2021-11-05
. Some analysts said that according to Bojian’s pricing, when 500,000 patients use the drug through the Medicare medical insurance provided by the US federal government for people over 65 years old, Aduhelm may spend about 29 billion U.
-
Sanofi's new-generation Pompe disease treatment is clinically approved in China
Time of Update: 2021-11-05
Text|Pharmaceutical Mission HillsAccording to the latest announcement on the official website of the Center for Drug Evaluation (CDE) of the State Food and Drug Administration, Sanofi (Sanofi) declared a new class 1 drug avalglucosidase alfa, which has obtained the implied license for clinical trials, and plans to develop an enzyme replacement for patients with early-onset Pompe disease Treatment .
-
Pfizer announces voluntary recall of all batches of smoking cessation drug varenicline in the U.S.
Time of Update: 2021-11-05
He also stated that the health benefits of quitting smoking outweigh the theoretical potential carcinogenic risk of nitrosamine impurities in varenicline .
In 2020, Chantix generated sales of US$919 million for Pfizer, a year-on-year decrease of approximately 17.
-
The US FDA granted accelerated approval to Baiyueze® (Zebutinib) for the treatment of relapsed or refractory marginal zone lymphoma
Time of Update: 2021-11-05
After Baiyueze® monotherapy, 20% of patients achieved complete remissionBaiyueze® is generally well tolerated and is consistent with its known safety characteristicsBeijing, China and Cambridge, Massachusetts, September 15, 2021/PRNewswire/ - BeiGene (Nasdaq: BGNE; Hong Kong Stock Exchange: 06160) is a global biopharmaceutical company focused on Develop and commercialize innovative drugs worldwide .
